NCT04682847: Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 89 Years (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: 
Exclusions: Patients with prior liver radiation, including radioembolization

Comments are closed.

Up ↑